Yup - agree with that - and with friend @footnort above.
I think the desired sequence would be:
- Fast-track designation
- Accelerated approval : ie conditional approval for clinical commercial use, with requirement for a follow up Ph 3 to confirm the clinical/survival benefit
- If they get that, then BP will be begging for a partnership or licensing deal, which would include their backing for the Ph 3
Things could move quite rapidly - for Azer-cel and Vaxinia.
With further good clinical benefit outcomes, IMU would get a deal, or deals, bringing cash flow and a partner to fund confirmatory Ph 3 trials.
Cheers
Dave
Yup - agree with that - and with friend @footnort above. I think...
-
- There are more pages in this discussion • 4,130 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $404.2M | |||
| Open | High | Low | Value | Volume |
| 5.6¢ | 5.7¢ | 5.5¢ | $379.9K | 6.840M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 1581916 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 680013 | 6 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |